Taking a treatment from the laboratory in to clinical trials and then to becoming available for use is a complex and expensive process. We talk with Dr Kiran Reddy, President and CEO of Praxis Precision Medicines, about the plans for the RC-222 treatment program with the eventual goal of having a treatment available for SCN2A gain-of-function epilepsies.

Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.

Leave a review and subscribe via Apple Podcasts. 

You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app

Links: 
Praxis Precision Medicines
Antisense oligonucleotide therapy for gain-of-function SCN2A epilepsies
Natural History Study – podcast on SCN2A natural history study

Taking a treatment from the laboratory in to clinical trials and then to becoming available for use is a complex and expensive process. We talk with Dr Kiran Reddy, President and CEO of Praxis Precision Medicines, about the plans for the RC-222 treatment program with the eventual goal of having a treatment available for SCN2A gain-of-function epilepsies.
Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.
Leave a review and&nbsp;subscribe via&nbsp;<a href="https://podcasts.apple.com/au/podcast/scn2a-insights/id1479681243?mt=2&amp;app=podcast">Apple Podcasts</a>.&nbsp;
You can also find SCN2A Insights on&nbsp;<a href="https://open.spotify.com/show/6KrDEmN7XPh8oDR7zR48cy">Spotify</a>, and&nbsp;<a href="https://podcasts.google.com/?feed=aHR0cHM6Ly93d3cub21ueWNvbnRlbnQuY29tL2QvcGxheWxpc3QvMjNkMTM3YTEtNDQxNi00MGQ2LWE1ZmMtYTUyOTAwMDFlY2RkLzA5MmMwZGNhLWQ0OTgtNDlkYy1hY2RkLWFhNzgwMGI3YWIyZC9jZDc2ZmU4Ni05MTA3LTQxMzYtYmY4Mi1hYTc4MDBiODVmZWQvcG9kY2FzdC5yc3M%3D">Google Podcasts</a>&nbsp;or in your podcast app
Links:&nbsp;
<ul>
<li><a href="https://www.praxismedicines.com/">Praxis Precision Medicines</a></li>
<li><a href="https://www.rogcon.com/wp-content/uploads/2018/11/AES-RogCon-SCN2A-poster-11_30_2018.pdf">Antisense oligonucleotide therapy for gain-of-function SCN2A epilepsies</a></li>
<li><a href="https://scn2aaustralia/podcast-2" data-wplink-url-error="true">Natural History Study</a>&nbsp;&ndash; podcast on SCN2A natural history study</li>
</ul>

Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders. Hosted by Ms Kris Pierce, RARE Global Advocacy Leadership Council member, and Dr David Cunnington, parents of Will, who has SCN2A.

Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders. Hosted by Ms Kris Pierce, RARE Global Advocacy Leadership Council member, and Dr David Cunnington, parents of Will, who has SCN2A.

SCN2A Insights brings you the latest research and clinical information on SCN2A from experts around the world.

SCN2A Insights

Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders.

Hosted by Ms Kris Pierce, RARE Global Advocacy Leadership Council member, and Dr David Cunnington, parents of Will, who has SCN2A.

Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders.
Hosted by Ms Kris Pierce, RARE Global Advocacy Leadership Council member, and Dr David Cunnington, parents of Will, who has SCN2A.

We talk with Dr Kiran Reddy, CEO of Praxis Precision Medicines, about the plans for the RC-222 treatment program with the eventual goal of having a treatment available for SCN2A gain-of-function epilepsies.

Advertisement